메뉴 건너뛰기




Volumn 92, Issue 8, 2013, Pages 1091-1100

Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: A single-center experience

Author keywords

Aclarubicin; Acute myeloid leukemia; Homoharringtonine; Re induction; Refractory; Relapsed

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE;

EID: 84880272005     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1758-5     Document Type: Article
Times cited : (29)

References (35)
  • 1
    • 45549083917 scopus 로고    scopus 로고
    • Treatment of relapsed acute myeloid leukaemia
    • 18473961 10.2174/157488706776876445 1:CAS:528:DC%2BD28XkvFyqs7k%3D
    • Kell J (2006) Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials 1:103-111
    • (2006) Rev Recent Clin Trials , vol.1 , pp. 103-111
    • Kell, J.1
  • 3
    • 0028077347 scopus 로고
    • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial
    • 7967730 1:STN:280:DyaK2M%2FlslaqsQ%3D%3D
    • Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8:1847-1853
    • (1994) Leukemia , vol.8 , pp. 1847-1853
    • Vogler, W.R.1    McCarley, D.L.2    Stagg, M.3    Bartolucci, A.A.4    Moore, J.5    Martelo, O.6    Omura, G.A.7
  • 4
    • 17344366634 scopus 로고    scopus 로고
    • Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
    • 9665189 10.1038/sj.leu.2401066 1:CAS:528:DyaK1cXkvVensLk%3D
    • Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049-1055
    • (1998) Leukemia , vol.12 , pp. 1049-1055
    • Kern, W.1    Aul, C.2    Maschmeyer, G.3    Schönrock-Nabulsi, R.4    Ludwig, W.D.5    Bartholomäus, A.6    Bettelheim, P.7    Wörmann, B.8    Büchner, T.9    Hiddemann, W.10
  • 5
    • 0032809362 scopus 로고    scopus 로고
    • A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study
    • 10475617 10.1016/S0145-2126(99)00087-9 1:CAS:528:DyaK1MXlvFSqu7k%3D
    • Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR (1999) A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 23:787-794
    • (1999) Leuk Res , vol.23 , pp. 787-794
    • Karanes, C.1    Kopecky, K.J.2    Head, D.R.3    Grever, M.R.4    Hynes, H.E.5    Kraut, E.H.6    Vial, R.H.7    Lichtin, A.8    Nand, S.9    Samlowski, W.E.10    Appelbaum, F.R.11
  • 8
    • 0025185703 scopus 로고
    • High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: A prospective randomized study
    • 2226729 10.1111/j.1600-0609.1990.tb00445.x 1:STN:280: DyaK3M%2FjtF2itw%3D%3D
    • Martiat P, Ghilain JM, Ferrant A, Doyen C, Delannoy A, Chatelain C, Bosly A, Michaux JL, Sokal G (1990) High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. Eur J Haematol 45:164-167
    • (1990) Eur J Haematol , vol.45 , pp. 164-167
    • Martiat, P.1    Ghilain, J.M.2    Ferrant, A.3    Doyen, C.4    Delannoy, A.5    Chatelain, C.6    Bosly, A.7    Michaux, J.L.8    Sokal, G.9
  • 11
    • 0027534992 scopus 로고
    • The management of recurrent acute myelogenous leukemia at a single center over a fifteen year period
    • 7683485 10.1111/j.1365-2141.1993.tb04664.x 1:STN:280:DyaK3s3kvFyktg%3D%3D
    • Davis C, Rohatiner A, Amess J, Lim J, Lister TA (1993) The management of recurrent acute myelogenous leukemia at a single center over a fifteen year period. Br J Haematol 83:404-411
    • (1993) Br J Haematol , vol.83 , pp. 404-411
    • Davis, C.1    Rohatiner, A.2    Amess, J.3    Lim, J.4    Lister, T.A.5
  • 13
    • 0030451886 scopus 로고    scopus 로고
    • Probability of long term disease free survival for acute myeloid leukemia patients after first relapse: A single center experience
    • 9006744 10.1093/oxfordjournals.annonc.a010796 1:STN:280: DyaK2s7lvFCjtg%3D%3D
    • Vignetti M, Orsini E, Petti MC, Moleti MR, Andrizzi C, Pinto RM, Amdori S, Meloni G (1996) Probability of long term disease free survival for acute myeloid leukemia patients after first relapse: a single center experience. Ann Oncol 7:933-938
    • (1996) Ann Oncol , vol.7 , pp. 933-938
    • Vignetti, M.1    Orsini, E.2    Petti, M.C.3    Moleti, M.R.4    Andrizzi, C.5    Pinto, R.M.6    Amdori, S.7    Meloni, G.8
  • 14
    • 38049153331 scopus 로고    scopus 로고
    • Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group
    • Polish Adult Leukemia Group 18076637 10.1111/j.1600-0609.2007.00988.x 1:CAS:528:DC%2BD1cXivFahsbo%3D
    • Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-KuÅ A, Polish Adult Leukemia Group (2008) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 80:115-126
    • (2008) Eur J Haematol , vol.80 , pp. 115-126
    • Wierzbowska, A.1    Robak, T.2    Pluta, A.3    Wawrzyniak, E.4    Cebula, B.5    Hołowiecki, J.6    Kyrcz-Krzemień, S.7    Grosicki, S.8    Giebel, S.9    Skotnicki, A.B.10    Piatkowska-Jakubas, B.11    Kuliczkowski, K.12    Kiełbiński, M.13    Zawilska, K.14    Kłoczko, J.15    Wrzesień-Kuå, A.16
  • 15
    • 33748931318 scopus 로고    scopus 로고
    • IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: A single-center experience
    • 16988532 10.1097/01.mjt.0000181690.21601.09
    • Yavuz S, Paydas S, Disel U, Sahin B (2006) IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther 13:389-393
    • (2006) Am J Ther , vol.13 , pp. 389-393
    • Yavuz, S.1    Paydas, S.2    Disel, U.3    Sahin, B.4
  • 16
    • 33746105303 scopus 로고    scopus 로고
    • Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia
    • 16791270 10.1038/sj.leu.2404287 1:CAS:528:DC%2BD28XntVWksro%3D
    • Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL (2006) Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20:1361-1367
    • (2006) Leukemia , vol.20 , pp. 1361-1367
    • Jin, J.1    Jiang, D.Z.2    Mai, W.Y.3    Meng, H.T.4    Qian, W.B.5    Tong, H.Y.6    Huang, J.7    Mao, L.P.8    Tong, Y.9    Wang, L.10    Chen, Z.M.11    Xu, W.L.12
  • 20
    • 0024268774 scopus 로고
    • Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro
    • 3199844 10.1016/0145-2126(88)90039-2 1:CAS:528:DyaL1MXltVyqtg%3D%3D
    • Kong XB, Fanucchi MP, Chou TC (1988) Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D- arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. Leuk Res 12:853-859
    • (1988) Leuk Res , vol.12 , pp. 853-859
    • Kong, X.B.1    Fanucchi, M.P.2    Chou, T.C.3
  • 21
    • 0025023047 scopus 로고
    • Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia
    • 2401166 1:STN:280:DyaK3czot1WgtA%3D%3D
    • Bian SG, Hao YS, Wang ZC (1990) Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia. Chung Hua Nei Ko Tsa Chih 29:22-25
    • (1990) Chung Hua Nei Ko Tsa Chih , vol.29 , pp. 22-25
    • Bian, S.G.1    Hao, Y.S.2    Wang, Z.C.3
  • 23
    • 0032836387 scopus 로고    scopus 로고
    • Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
    • 10525830 10.1007/s002770050541 1:CAS:528:DyaK1MXlvFKmurk%3D
    • Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V, Dias Wickramanayake P (1999) Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 78:418-425
    • (1999) Ann Hematol , vol.78 , pp. 418-425
    • Steinmetz, H.T.1    Schulz, A.2    Staib, P.3    Scheid, C.4    Glasmacher, A.5    Neufang, A.6    Franklin, J.7    Tesch, H.8    Diehl, V.9    Dias Wickramanayake, P.10
  • 29
    • 0034988112 scopus 로고    scopus 로고
    • Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial
    • UK MRC Adult Leukemia Working Party 11380463 10.1046/j.1365-2141.2001. 02785.x 1:STN:280:DC%2BD3M3pvVGgsQ%3D%3D
    • Liu Yin JA, Wheatley K, Rees JK, Burnett AK, UK MRC Adult Leukemia Working Party (2001) Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 113:713-726
    • (2001) Br J Haematol , vol.113 , pp. 713-726
    • Liu Yin, J.A.1    Wheatley, K.2    Rees, J.K.3    Burnett, A.K.4
  • 32
    • 3943062139 scopus 로고    scopus 로고
    • Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia
    • 15339685 1:CAS:528:DC%2BD2MXjsF2jsbo%3D
    • Ferrara F, Palmieri S, Mele G (2004) Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 89:998-1008
    • (2004) Haematologica , vol.89 , pp. 998-1008
    • Ferrara, F.1    Palmieri, S.2    Mele, G.3
  • 33
    • 0033975925 scopus 로고    scopus 로고
    • Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities
    • for the German AML Cooperative Group 10673737 10.1038/sj.leu.2401668 1:STN:280:DC%2BD3c7jvFGnsw%3D%3D
    • Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W, for the German AML Cooperative Group (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 14:226-231
    • (2000) Leukemia , vol.14 , pp. 226-231
    • Kern, W.1    Schoch, C.2    Haferlach, T.3    Braess, J.4    Unterhalt, M.5    Wormann, B.6    Buchner, T.7    Hiddemann, W.8
  • 34
    • 0034009065 scopus 로고    scopus 로고
    • Treatment of relapsed and refractory acute myelogenous leukemia
    • 10720145 10.1038/sj.leu.2401568 1:CAS:528:DC%2BD3cXit1akt7w%3D
    • Estey E (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14:476-479
    • (2000) Leukemia , vol.14 , pp. 476-479
    • Estey, E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.